Last reviewed · How we verify
Bendamustine hydrochloride injection
Bendamustine is an alkylating agent that cross-links DNA strands, causing cell death in rapidly dividing cancer cells.
Bendamustine is an alkylating agent that cross-links DNA strands, causing cell death in rapidly dividing cancer cells. Used for Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma.
At a glance
| Generic name | Bendamustine hydrochloride injection |
|---|---|
| Also known as | bendamustine hydrochloride |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bendamustine functions as a bifunctional alkylating agent that covalently binds to DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription. This leads to apoptosis in malignant cells. Unlike classical alkylating agents, bendamustine also has immunomodulatory properties that may enhance its anti-tumor activity.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Non-Hodgkin's lymphoma (NHL)
- Hodgkin's lymphoma
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Infection
- Diarrhea
- Fever
Key clinical trials
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (PHASE3)
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (PHASE1)
- CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (PHASE2)
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (PHASE1, PHASE2)
- A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL (PHASE3)
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL (PHASE3)
- Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: